<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1A83FE4-2611-432F-957A-02073AAE23B1"><gtr:id>D1A83FE4-2611-432F-957A-02073AAE23B1</gtr:id><gtr:name>Cognetix</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AB2DDF82-9C96-4248-A6A1-DDCA3F607A18"><gtr:id>AB2DDF82-9C96-4248-A6A1-DDCA3F607A18</gtr:id><gtr:name>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/57150975-2FFC-442F-A99E-ABD25A46F8D2"><gtr:id>57150975-2FFC-442F-A99E-ABD25A46F8D2</gtr:id><gtr:name>Pasteur Institute, Paris</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1971DE66-86B6-45D7-8CE0-39600A6FCCD6"><gtr:id>1971DE66-86B6-45D7-8CE0-39600A6FCCD6</gtr:id><gtr:name>Goethe University of Frankfurt am Main</gtr:name><gtr:address><gtr:line1>Max von Laue Str. 7</gtr:line1><gtr:line4>Frankfurt-am-Main</gtr:line4><gtr:postCode>60438</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Physiology Anatomy and Genetics</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1A83FE4-2611-432F-957A-02073AAE23B1"><gtr:id>D1A83FE4-2611-432F-957A-02073AAE23B1</gtr:id><gtr:name>Cognetix</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB2DDF82-9C96-4248-A6A1-DDCA3F607A18"><gtr:id>AB2DDF82-9C96-4248-A6A1-DDCA3F607A18</gtr:id><gtr:name>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/57150975-2FFC-442F-A99E-ABD25A46F8D2"><gtr:id>57150975-2FFC-442F-A99E-ABD25A46F8D2</gtr:id><gtr:name>Pasteur Institute, Paris</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1971DE66-86B6-45D7-8CE0-39600A6FCCD6"><gtr:id>1971DE66-86B6-45D7-8CE0-39600A6FCCD6</gtr:id><gtr:name>Goethe University of Frankfurt am Main</gtr:name><gtr:address><gtr:line1>Max von Laue Str. 7</gtr:line1><gtr:line4>Frankfurt-am-Main</gtr:line4><gtr:postCode>60438</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FAA51396-5490-4A7E-AD18-F5FC3DE42172"><gtr:id>FAA51396-5490-4A7E-AD18-F5FC3DE42172</gtr:id><gtr:firstName>Stephanie</gtr:firstName><gtr:surname>Cragg</gtr:surname><gtr:orcidId>0000-0001-9677-2256</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5AEC18C1-EF73-4333-A676-91CE3C0D44B2"><gtr:id>5AEC18C1-EF73-4333-A676-91CE3C0D44B2</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Exley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700932"><gtr:id>629925D1-6A13-4F64-8E29-C35760C0E583</gtr:id><gtr:title>Identifying the alpha6 nicotinic receptor subtypes that govern the control of striatal dopamine transmission by nicotine</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700932</gtr:grantReference><gtr:abstractText>Tobacco smoking is one of the largest preventable causes of illness and death worldwide. The Royal College of Physicians have estimated that smoking-related ill health generates at least 1,000 hospital admissions per day in England alone, and is the cause of a fifth of all UK deaths. Although these detrimental effects on our health can readily be prevented by stopping smoking, in practice as any smoker knows, giving up the habit is difficult. Smoking is addictive. We urgently need to improve the means available to smokers to aid their chances of extinguishing a smoking habit once and for all. In order to do this it is essential that we improve our understanding of the fundamental mechanisms of how nicotine acts in the brain. We already know that like cocaine and amphetamine, nicotine is addictive because it increases levels of the neurochemical dopamine in brain centres related to reward where nicotine mimics the effects of natural rewards. But we do not understand how nicotine can do this. In particular, we have still not fully identified the molecules, or neurochemical receptors, on nerve cell membranes that nicotine binds to and that are responsible for enhancing dopamine in these reward centres. 
The work we propose will identify which of nicotine?s many receptors are the receptors central to nicotine?s addictive properties. We will deduce which receptors are most important by using a state-of-the-art method to detect the effects of nicotine on dopamine in these brain centres in mice who carry different types of these receptors. If we can identify the right receptor, we will have found a target site for action for a future pharmaceutical treatment to combat nicotine addiction.</gtr:abstractText><gtr:technicalSummary>Nicotine addiction through tobacco smoking is amongst the largest single preventable causes of morbidity and premature mortality in the world. Yet, we still lack complete knowledge of the fundamental neuronal mechanisms underlying nicotine action, and certainly lack definitive treatments for nicotine addiction. Striatal dopamine transmission is a key player in the development of nicotine addiction. Despite detailed characterization of the diverse stoichiometries of the heteromeric nicotinic receptors expressed within striatum, little is known about the functional relevance of each receptor type in nicotine?s actions. Alpha6-subunit-containing (alpha6*) receptors are attracting much attention as promising targets for pharmacotherapies in dopaminergic disorders because unlike other subunits, their expression is relatively restricted to dopamine neurons. Moreover, we now have unpublished data to suggest that alpha6*-receptors play a previously unappreciated dominant role in the control of dopamine neurotransmission by nicotine in the nucleus accumbens (Exley et al., submitted). 
Alpha6*-receptors are proposed to exist in three forms variously containing alpha4 and beta3 co-subunits (Salminen et al., 2007). In this project, we will identify the alpha6*-receptors responsible for the control of striatal dopamine neurotransmission by nicotine and endogenous acetylcholine. The effects of nicotine on dopamine neurotransmission depend critically on endogenous striatal acetylcholine (Rice and Cragg 2004, Cragg 2006). We will use real-time electrochemical technologies, namely fast-scan cyclic voltammetry to detect synaptic dopamine transients with subsecond time resolution at carbon-fibre microelectrodes in acutely living slices of mouse striatum where acetylcholine neuron activity is intact. We will identify the function of the diverse portfolio of alpha6*-receptors in the control of dopamine neurotransmission using transgenic mice with subunit-specific deletions (alpha6, alpha4, beta3) in combination with pharmacological tools. Since nicotinic receptor control of dopamine transmission is specific to the frequency of action potentials reaching the dopamine synapse (Rice and Cragg 2004; Zhang and Sulzer 2004), the design of these experiments will necessarily involve exploring dopamine transients released across the range of physiologically relevant activity in dopamine neurons including low frequency tonic ( 10 Hz) and high-frequency reward-related activity (20-100 Hz). 
These experiments should reveal the identity (alpha and beta subunit composition) of the alpha6-receptors responsible for the powerful control of endogenous dopamine neurotransmission by nicotine. These data will not only enhance our understanding of nicotine?s synaptic mechanisms of action but moreover, should also provide a key therapeutic target for the design of pharmaceutical strategies to treat nicotine addiction as well as other disorders of dopamine dysfunction including Parkinson?s disease.</gtr:technicalSummary><gtr:fund><gtr:end>2011-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>348103</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Muscarinic receptor function</gtr:description><gtr:id>716D554E-B5EC-4594-AE9F-07ADB4B75889</gtr:id><gtr:impact>Mansucript by Threlfell et al 2010 Journal of Neuroscience</gtr:impact><gtr:outcomeId>tjzdi1uAMR8-1</gtr:outcomeId><gtr:partnerContribution>Supply of muscarinic receptor knockout mice</gtr:partnerContribution><gtr:piContribution>Exploration of muscarinic receptor control of striatal dopamine release</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Physiology, Anatomy and Genetics</gtr:department><gtr:description>Study of synuclein function and BAC transgenic models of Parkinson's disease</gtr:description><gtr:id>5F88BCD7-DAC2-4995-A63D-2F2FE071E7B2</gtr:id><gtr:impact>Senior et al, Eur J Neurosci, 2007
Janezic et al
Taylor et al</gtr:impact><gtr:outcomeId>aTVRJktmAM1-1</gtr:outcomeId><gtr:partnerContribution>Supply of novel genotypes and mouse models of Parkinson's disease</gtr:partnerContribution><gtr:piContribution>Study of dopamine synapse function</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cognetix</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Use of alpha-conotoxin</gtr:description><gtr:id>987803F3-3549-4E2D-B65B-6EE04536A7C7</gtr:id><gtr:impact>Contributes towards findings that have been publihsed (Exley et al., 2008; Threlfell et al., 2010, Exley et al 2012)</gtr:impact><gtr:outcomeId>3A0A36FC75F-1</gtr:outcomeId><gtr:partnerContribution>Supply of key pharmacological agents</gtr:partnerContribution><gtr:piContribution>We use the toxin supplied by Cognetix to investigate the role of alpha6-subunit-containing receptors in the control of striatal dopamine transmission</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pasteur Institute, Paris</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>alpha-4 and alpha-6 knockouts</gtr:description><gtr:id>D35BD792-5F4A-4817-A210-3FBE2E824B04</gtr:id><gtr:impact>Contributes towards findings that have been presented at meetings, are in manuscripts under review and will form basis of new applications. Work also informs other ongoing research in the lab</gtr:impact><gtr:outcomeId>E0A6334A0C5-1</gtr:outcomeId><gtr:partnerContribution>Supply of key transgenic animals</gtr:partnerContribution><gtr:piContribution>We undertake neurochemical investigations in these mice to identify the function of these specific nicotinic receptors</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Anatomical Neuropharmacology Unit</gtr:department><gtr:description>Oxford Parkinson's Disease Centre</gtr:description><gtr:id>C968186E-F075-4066-8F18-38B1810188B1</gtr:id><gtr:impact>MAnuscripts published, and abstracts presented at national and international meetings. 
This is a major multidisciplinary collaboration (&amp;pound;10million total income) to fund a research centre (Oxford Parkinson's Disease Centre)</gtr:impact><gtr:outcomeId>YxBbzhignkD-1</gtr:outcomeId><gtr:partnerContribution>Supply of novel transgenic animal models of PD, study of accompanying pathology, imaging of affected pathways,</gtr:partnerContribution><gtr:piContribution>STudy of dopamine synapse function in novel animal models of Parkinson's disease</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Goethe University Frankfurt</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>A53T synuclein</gtr:description><gtr:id>F443CCB5-D5A7-488A-87CC-0843208E033E</gtr:id><gtr:impact>Poster presentations at Meeting of Parkinson's UK, York 2010</gtr:impact><gtr:outcomeId>RWn1AwHyYi9-1</gtr:outcomeId><gtr:partnerContribution>Supply of A53T-PrP transgenic mouse model of Parkinson's disease</gtr:partnerContribution><gtr:piContribution>Study of DA synapse fucntion in mouse model of PD</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pasteur Institute, Paris</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Department of Neuroscience</gtr:department><gtr:description>Alpha5</gtr:description><gtr:id>201D2D3A-C6C3-48F7-9F43-39EDFB6C9957</gtr:id><gtr:impact>Publication Exley et al 2012
New grant funded by Parkinson's UK</gtr:impact><gtr:outcomeId>MxNJqoez8k6-1</gtr:outcomeId><gtr:partnerContribution>SUpply of novel transgenic animals and vectors</gtr:partnerContribution><gtr:piContribution>Study of function of alpha5 subunits in nicotinic receptor control of dopamine transmission</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Parkinson's group talk Hereford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>90B7B427-059A-453C-BA3F-7BDB342A61C9</gtr:id><gtr:impact>Share knowledge, stimulate interest

After the talk, audience asked to visit lab</gtr:impact><gtr:outcomeId>56950c8c9e9b19.69587590</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Speaker and Opening of fundraising walk for Parkinson's UK, Oxford</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>45FEB793-9F8B-49E7-88B8-928A39583B32</gtr:id><gtr:impact>Speaker and Opening of fundraising walk for Parkinson's UK, Oxford</gtr:impact><gtr:outcomeId>5880ecfa90e475.66556065</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:url>https://www.parkinsons.org.uk/content/walk-parkinsons</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Discuss Parkinson's research with individual fundraisers (DB, EL, SB)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9D7DAE63-2624-4A87-8715-309841D6A92B</gtr:id><gtr:impact>Engagement with small groups of charitable donors to promote fundraising into Parkinson's research</gtr:impact><gtr:outcomeId>5880eda5a9dd76.24860449</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2009,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Innovations article 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A7EBB7B0-1CF1-437E-90A5-EBDF40B40E9F</gtr:id><gtr:impact>Publication in internationally reaching magazine.
results not yet clear.

Not yet clear</gtr:impact><gtr:outcomeId>545a3a7ef3ba16.13772262</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:url>http://www.internationalinnovation.com/hope-for-dopamine-disorders/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interviewed by local radio station 2009</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E8AB1F01-2A2E-4EED-9400-3EC9629D3CE6</gtr:id><gtr:impact>Interviewed about use of nicotine in Parkinson's disease

N/A</gtr:impact><gtr:outcomeId>AFF832D0C2B</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Neuroscience exhibition in the Oxford museum of Science  March 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5413D617-2AFF-4A72-9775-24425FD5D7DE</gtr:id><gtr:impact>Neuroscience exhibition in the Oxford museum of Science March 2014


Unknown</gtr:impact><gtr:outcomeId>54b6854cc126c3.19785868</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brain Awareness week 2013 RE 2</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CAB73097-B573-4D6F-88DE-428BD071B983</gtr:id><gtr:impact>encouraged discussions about how the brain works and greater awareness of diseases such as PD and effects of tobacco

Unknown</gtr:impact><gtr:outcomeId>54648fdae8e9b2.20984160</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brain Awareness week 2013 RE 1</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>48D032EE-A9DD-480A-A2D2-1764CCB5787C</gtr:id><gtr:impact>talk sparked questions and discussion afterwards

Unknown</gtr:impact><gtr:outcomeId>54648f7197cde3.55252469</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Edinburgh International Science Festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D7DFFB9B-354F-432B-9AAD-32D79678C4C2</gtr:id><gtr:impact>Talk sparked questions and debate

N/A</gtr:impact><gtr:outcomeId>56950bf19a4004.94460715</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.sciencefestival.co.uk/mediaLibrary/other/english/6285.pdf</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public visit 2009</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5A7FFD14-03DD-44DE-9834-EE51558D5F6D</gtr:id><gtr:impact>Host science visit to members of the Parkinson's disease Society

N/A</gtr:impact><gtr:outcomeId>EB48F6C98CC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>177083</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Parkinson's Disease UK Project Grant 2008</gtr:description><gtr:end>2011-08-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:id>0E119963-9A03-4F8A-95EF-C2962C48AF31</gtr:id><gtr:outcomeId>8A61E8B7BBF0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>61000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC-DTA DPhil studensthip 2010</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7CE37E10-76A5-43F1-A3BB-8D86F166F8E1</gtr:id><gtr:outcomeId>FLJdxwNUz6V0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>IBRO Studentship</gtr:description><gtr:end>2008-03-02</gtr:end><gtr:fundingOrg>International Brain Research Organisation (IBRO)</gtr:fundingOrg><gtr:id>0A4E0817-7886-45FA-8892-E6EE12B61A5A</gtr:id><gtr:outcomeId>WCZi81L5TAf0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>110000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Clarendon Fund</gtr:department><gtr:description>DPhil Studentship BR</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>C73796D6-19B6-479B-9434-AA8468A58226</gtr:id><gtr:outcomeId>5880ebaa8a5754.60444350</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>145451</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Parkinson's UK Project Grant 2011</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:id>C6D2228A-A144-47D3-B633-3F3CD9066EDB</gtr:id><gtr:outcomeId>TzoMnyVhfdZ0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>369497</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project grant KJ 2012</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>290B9DF1-4EFC-4BD9-B10A-675B58AB1EE2</gtr:id><gtr:outcomeId>kkEYbME6YBg0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Monument Trust Discovery Award Renewal 2015</gtr:description><gtr:end>2020-02-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>J-1403</gtr:fundingRef><gtr:id>67E0E6D2-8867-4082-AC59-D508C54574D2</gtr:id><gtr:outcomeId>545a341428c1a5.42331935</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>92993</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Parkinson's UK PhD Studentship 2010</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:id>04558BA2-8E72-4253-A44F-FF3AF83E1C51</gtr:id><gtr:outcomeId>M4UeP7mouB20</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clarendon Fund Studentship 2011</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>4C87CBFB-1C5E-43DA-9A31-4F4D7FB0D1BD</gtr:id><gtr:outcomeId>Jvm3sNMpNat</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>61000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC-DTA DPhil Studentship 2009</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>4BBC2877-FA63-476D-83E7-AD1FD0E32CB8</gtr:id><gtr:outcomeId>219C3AD9F670</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>34986</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Parkinson's UK Innovation Grant 2013</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>K-1209</gtr:fundingRef><gtr:id>34A134DE-313B-4551-83CC-EE608E1D7AF3</gtr:id><gtr:outcomeId>pyhpFse7bEf</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>297158</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Parkinson's UK Project Grant 2015</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>G1504</gtr:fundingRef><gtr:id>EE8C8C0A-38C8-49D5-BC42-D32BE65FB1F0</gtr:id><gtr:outcomeId>5695092c22cd72.76854776</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>164250</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Parkinson's Disease UK Project Grant 2008</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:id>2E578E60-2835-4A72-B3AD-B22114DB7D48</gtr:id><gtr:outcomeId>NMqVwCJ7tmK0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Monument Trust Discovery Award 2010</gtr:description><gtr:end>2015-02-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:fundingRef>J-0901</gtr:fundingRef><gtr:id>1748DA82-A1B9-46B5-9135-3AEA9C052513</gtr:id><gtr:outcomeId>MyHq7ukEsgS</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>An approach to studying the control of striatal dopamine transmissoin, that uses a novel but key range of stimulus parameters that exposes powerful and activity-dependent mechanisms that control of transmission.</gtr:description><gtr:id>75666870-7A72-446A-8E58-532CAC992A46</gtr:id><gtr:impact>Has aided understanding of other striatal systems e.g. opioid receptor function (Britt and McGehee, Journal of Neuroscience, 2008), D2 and nachrs (Zhang et al 2009, Mol Pharmacol; Zhang et al 2010, J Neurosci)</gtr:impact><gtr:outcomeId>75037C92163</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Stimulation protocol</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4C564F08-097C-4EC7-A104-B33DFC66C090</gtr:id><gtr:title>a-Synuclein and dopamine at the crossroads of Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Trends in neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4f1d2a8060a39b9dd945404e16d0299"><gtr:id>c4f1d2a8060a39b9dd945404e16d0299</gtr:id><gtr:otherNames>Venda LL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0166-2236</gtr:issn><gtr:outcomeId>MCcZ1GREgfZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>274107DA-0F00-459B-88D3-4B26CDD2EFA8</gtr:id><gtr:title>Dopamine signaling in dorsal versus ventral striatum: the dynamic role of cholinergic interneurons.</gtr:title><gtr:parentPublicationTitle>Frontiers in systems neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93781f86c6ff76bc7e1dcaed93e9488c"><gtr:id>93781f86c6ff76bc7e1dcaed93e9488c</gtr:id><gtr:otherNames>Threlfell S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1662-5137</gtr:issn><gtr:outcomeId>W8wPaBVvo7W</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6675F4F4-C146-4144-9181-E87612124EEE</gtr:id><gtr:title>Striatal dopamine transmission is reduced after chronic nicotine with a decrease in a6-nicotinic receptor control in nucleus accumbens.</gtr:title><gtr:parentPublicationTitle>The European journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/370ffa7cd9196023d804bd57feb6dde4"><gtr:id>370ffa7cd9196023d804bd57feb6dde4</gtr:id><gtr:otherNames>Exley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0953-816X</gtr:issn><gtr:outcomeId>pm_15779_29_23841846</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADE37A69-3554-43FD-97C6-1E002027B9F2</gtr:id><gtr:title>Striatal muscarinic receptors promote activity dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93781f86c6ff76bc7e1dcaed93e9488c"><gtr:id>93781f86c6ff76bc7e1dcaed93e9488c</gtr:id><gtr:otherNames>Threlfell S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>PSV5JS2Qaam</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7297008E-C7CE-4894-BCD2-52EF42070CF7</gtr:id><gtr:title>Substance P Weights Striatal Dopamine Transmission Differently within the Striosome-Matrix Axis.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e595a79b0bb73260843d5fc572664497"><gtr:id>e595a79b0bb73260843d5fc572664497</gtr:id><gtr:otherNames>Brimblecombe KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>5673ea9792d564.75200358</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91013FCB-3A1E-4311-9E86-6CF34C2E4571</gtr:id><gtr:title>Pauses in Striatal Cholinergic Interneurons: What is Revealed by Their Common Themes and Variations?</gtr:title><gtr:parentPublicationTitle>Frontiers in systems neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/110977d271afa6909e4c34ea54267267"><gtr:id>110977d271afa6909e4c34ea54267267</gtr:id><gtr:otherNames>Zhang YF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1662-5137</gtr:issn><gtr:outcomeId>5a58a550859921.52285726</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A6C67D2-9180-4427-A41F-D5D6736BA517</gtr:id><gtr:title>Striatal dopamine neurotransmission: regulation of release and uptake.</gtr:title><gtr:parentPublicationTitle>Basal ganglia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b6bd6a9f7ec85a661959fd1535e37bc"><gtr:id>5b6bd6a9f7ec85a661959fd1535e37bc</gtr:id><gtr:otherNames>Sulzer D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2210-5336</gtr:issn><gtr:outcomeId>56d5d3949d4390.90274580</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7DDBD84-B9B5-49C7-8BC0-DBE5B404AD31</gtr:id><gtr:title>Impaired intracellular trafficking defines early Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Trends in neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5385a9e8b86d7db96a0c0b7c8aed003"><gtr:id>f5385a9e8b86d7db96a0c0b7c8aed003</gtr:id><gtr:otherNames>Hunn BH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0166-2236</gtr:issn><gtr:outcomeId>5673ea97680219.35506378</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96132FFB-4214-44A0-97A5-FD4751B883E9</gtr:id><gtr:title>Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein.</gtr:title><gtr:parentPublicationTitle>The European journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e414614c9aa1ee9d0b662f07623eb62"><gtr:id>4e414614c9aa1ee9d0b662f07623eb62</gtr:id><gtr:otherNames>Senior SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0953-816X</gtr:issn><gtr:outcomeId>bvd5hJ3TVvv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EE1840D-7A5C-47BA-A730-FC316CBFDB2F</gtr:id><gtr:title>Representation of spontaneous movement by dopaminergic neurons is cell-type selective and disrupted in parkinsonism.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0630e02feac27cd5406058fc71abc53a"><gtr:id>0630e02feac27cd5406058fc71abc53a</gtr:id><gtr:otherNames>Dodson PD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>585d36ab9ef8e0.58504692</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA2C30B7-6986-4726-95F4-7598B66BB941</gtr:id><gtr:title>Constitutive histamine H2 receptor activity regulates serotonin release in the substantia nigra.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93781f86c6ff76bc7e1dcaed93e9488c"><gtr:id>93781f86c6ff76bc7e1dcaed93e9488c</gtr:id><gtr:otherNames>Threlfell S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>cLBuX3u4Nc5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3412455-77F9-49E7-B3E4-D156055B6745</gtr:id><gtr:title>The impact of a parkinsonian lesion on dynamic striatal dopamine transmission depends on nicotinic receptor activation.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/281e8ccd9dac9521ceadfbc748fd53c9"><gtr:id>281e8ccd9dac9521ceadfbc748fd53c9</gtr:id><gtr:otherNames>Jennings KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>5673ea97ba24a4.70962832</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FAF04EA-E145-498A-A2AC-AC0A6D0BE4F8</gtr:id><gtr:title>Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/370ffa7cd9196023d804bd57feb6dde4"><gtr:id>370ffa7cd9196023d804bd57feb6dde4</gtr:id><gtr:otherNames>Exley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>J1ggZC2vkCV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>513C9292-2134-462A-A438-097537D30EB4</gtr:id><gtr:title>Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/370ffa7cd9196023d804bd57feb6dde4"><gtr:id>370ffa7cd9196023d804bd57feb6dde4</gtr:id><gtr:otherNames>Exley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>nTWsY7J1XRK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FB66AAF-2EA2-4B64-815A-3BF3AE899CCF</gtr:id><gtr:title>5-HT(1B) receptor regulation of serotonin (5-HT) release by endogenous 5-HT in the substantia nigra.</gtr:title><gtr:parentPublicationTitle>Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93781f86c6ff76bc7e1dcaed93e9488c"><gtr:id>93781f86c6ff76bc7e1dcaed93e9488c</gtr:id><gtr:otherNames>Threlfell S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0306-4522</gtr:issn><gtr:outcomeId>YQzGjTTJqJW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD23BB00-6369-4C00-BF1E-559ED4431B32</gtr:id><gtr:title>Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93781f86c6ff76bc7e1dcaed93e9488c"><gtr:id>93781f86c6ff76bc7e1dcaed93e9488c</gtr:id><gtr:otherNames>Threlfell S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>pm_15779_29_22794260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3D3A04D-EB9F-409E-9A71-14F0E6A121A0</gtr:id><gtr:title>Striatal a5 nicotinic receptor subunit regulates dopamine transmission in dorsal striatum.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/370ffa7cd9196023d804bd57feb6dde4"><gtr:id>370ffa7cd9196023d804bd57feb6dde4</gtr:id><gtr:otherNames>Exley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>pm_15779_29_22396410</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D028879-94E3-4B19-9856-459EEB633334</gtr:id><gtr:title>Non-linear relationship between 5-HT transporter gene expression and frequency sensitivity of 5-HT signals.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/281e8ccd9dac9521ceadfbc748fd53c9"><gtr:id>281e8ccd9dac9521ceadfbc748fd53c9</gtr:id><gtr:otherNames>Jennings KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>eyy7bgvc34G</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D7B08D1-3504-43DB-90EC-CA8CEF15B065</gtr:id><gtr:title>Cortical Control of Striatal Dopamine Transmission via Striatal Cholinergic Interneurons.</gtr:title><gtr:parentPublicationTitle>Cerebral cortex (New York, N.Y. : 1991)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d6668951c862e0eb1aa2f5013bccfb1"><gtr:id>4d6668951c862e0eb1aa2f5013bccfb1</gtr:id><gtr:otherNames>Kosillo P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1047-3211</gtr:issn><gtr:outcomeId>585d37d2335947.18398449</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A66158F9-5928-410A-ADE4-B48F8A3D8980</gtr:id><gtr:title>Dopamine release in the basal ganglia.</gtr:title><gtr:parentPublicationTitle>Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c0283ab9bd4eedd72d44100945eb4db"><gtr:id>9c0283ab9bd4eedd72d44100945eb4db</gtr:id><gtr:otherNames>Rice ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0306-4522</gtr:issn><gtr:outcomeId>XdUuNdt7db3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DD7221E-F8D5-49E8-9CE0-DC2667471D00</gtr:id><gtr:title>Compendium of In Vivo Monitoring in Real-Time Molecular Neuroscience - Volume 1: Fundamentals and Applications</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d6668951c862e0eb1aa2f5013bccfb1"><gtr:id>4d6668951c862e0eb1aa2f5013bccfb1</gtr:id><gtr:otherNames>Kosillo P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:isbn>978-981-4619-76-9</gtr:isbn><gtr:outcomeId>545a28f834f275.55898950</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5D34335-DEDB-4288-8A22-7C7A4D337201</gtr:id><gtr:title>Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway.</gtr:title><gtr:parentPublicationTitle>Brain research reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c0283ab9bd4eedd72d44100945eb4db"><gtr:id>9c0283ab9bd4eedd72d44100945eb4db</gtr:id><gtr:otherNames>Rice ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0165-0173</gtr:issn><gtr:outcomeId>C5Z2a3C6Uve</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>967C4668-53E2-4FB9-8DD6-B291ECE952B6</gtr:id><gtr:title>The Striosome and Matrix Compartments of the Striatum: A Path through the Labyrinth from Neurochemistry toward Function.</gtr:title><gtr:parentPublicationTitle>ACS chemical neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e595a79b0bb73260843d5fc572664497"><gtr:id>e595a79b0bb73260843d5fc572664497</gtr:id><gtr:otherNames>Brimblecombe KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1948-7193</gtr:issn><gtr:outcomeId>5a58a50339b3a7.73927316</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9FF9547-0423-4C50-9DA3-961F08010E87</gtr:id><gtr:title>LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fded70b9f465cf72ff34f64458ec5356"><gtr:id>fded70b9f465cf72ff34f64458ec5356</gtr:id><gtr:otherNames>Sloan M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5a58a50361c8d4.64910611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D542803-3D25-4475-ACD3-8D91BDD7BA27</gtr:id><gtr:title>Distinct contributions of nicotinic acetylcholine receptor subunit alpha4 and subunit alpha6 to the reinforcing effects of nicotine.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/370ffa7cd9196023d804bd57feb6dde4"><gtr:id>370ffa7cd9196023d804bd57feb6dde4</gtr:id><gtr:otherNames>Exley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>aHRHoWoPHfk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0BE8B3E-8747-4A7C-837F-7E2D9F68C904</gtr:id><gtr:title>Maintaining network activity in submerged hippocampal slices: importance of oxygen supply.</gtr:title><gtr:parentPublicationTitle>The European journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ecf6e1a3942174ea7cd030ee6b2970d"><gtr:id>7ecf6e1a3942174ea7cd030ee6b2970d</gtr:id><gtr:otherNames>H?jos N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0953-816X</gtr:issn><gtr:outcomeId>Ggv19nzJLAf</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700932</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>